Tecentriq (atezolizumab) — Coverage and Authorization Policy
Customize your policy alerts
Sign up for Viva Health Policy IC-0278 alerts
Get alerted when Policy IC-0278 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, dosing limits, length of authorization, and clinical coverage criteria for intravenous atezolizumab (Tecentriq) for Viva Health members across multiple cancer indications.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.